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Abstract: Recent advances in breast cancer management might make
the use of postmastectomy radiotherapy (PMRT) redundant in the
treatment of pT1/T2N1 patients. We investigated the impact of PMRT
on disease-free survival (DFS) in these patients who have a low risk of
locoregional recurrence (LRR) after contemporary multidisciplinary
management.
Between 1998 and 2011, 1123 patients underwent upfront surgery
for pathologically diagnosed pT1/T2N1 breast cancer, at a single
institution. A retrospective review was performed on 692 patients
who had a mastectomy with axillary lymph node (LN) clearance. Most
patients received adjuvant systemic chemotherapy and/or endocrine
therapy. PMRT was administered to 17.8% of the patients. The median
follow-up time was 98 months.
The entire cohort was divided into 2 groups, the early-era (1998–
2003) and late-era (2004–2011) cohorts. Grouping was based on the use
of modern therapies since 2004 including sentinel LN (SLN) biopsy,
anthracycline/taxane-based chemotherapy, and aromatase inhibitors. La-
te-era patients had a significantly lower 5-year LRR compared with early-
era patients (3.2% vs 10.3%, respectively;P< 0.001). In late-era patients,
although PMRT did not significantly reduce the 5-year LRR rate (1% vs
3.8%, respectively), it did improve the 5-year DFS rate (96.1% vs 87.5%,
respectively). After controlling for all clinicopathological variables,
PMRT was independently associated with improved DFS. In subgroup
analysis, depending on the presence of micro- or macrometastasis in theD, PhD, Hyun C D, PhD,
MD, PhD, and Yong Bae Kim, MD, PhD
(0%, 5.2%, and 9.8% in micrometastasis, SLN macrometastasis, and non-
SLN macrometastasis, respectively).
Advanced surgical and systemic therapies might not negate the
benefit of PMRT in recently diagnosed pN1 patients who have a very
low risk for LRR. Our data indicate that the overall recurrence risk
combined with the LRR should be considered for an indication of PMRT,
and raises the question of whether the receipt of PMRT would improve
outcome in patients with micrometastasis.
(Medicine 94(33):e1259)
Abbreviations: ACT = cyclophosphamide, doxorubicin, and/or
paclitaxel, CI = confidence interval, DFS = disease-free survival,
DM = distant metastasis, EBCTCG = Early Breast Cancer Trialists’
Collaborative Group, ER = estrogen receptor, HER2 = human
epidermal growth factor receptor 2, HR = hazard ratio, LN = lymph
node, LRR = locoregional recurrence, OS = overall survival, PMRT
= postmastectomy radiotherapy, PR = progesterone receptor, SLN
= sentinel lymph node.
INTRODUCTION
I n breast cancer patients, anatomic staging, especially nodalstatus, is considered a significant factor for the prognosis of
locoregional recurrence (LRR) and selection of adjuvant radi-
ation therapy after mastectomy. The survival benefit of post-
mastectomy radiotherapy (PMRT) in node-positive breast
cancer patients has been well established through multiple-
randomized trials.1–3 The results of Early Breast Cancer Tri-
alists’ Collaborative Group (EBCTCG) meta-analyses con-
firmed that PMRT consistently reduced the risk of LRR by
two-thirds and increased disease-free survival (DFS) and can-
cer-specific survival.4 Although there is an international con-
sensus that PMRT should be indicated for patients with tumors
that measure >5 cm or for those with 4 positive lymph nodes
(LNs), the role of PMRT in patients who have tumors that
measure 5 cm and 1 to 3 positive LNs (pT1–2N1) is highly
controversial because axillary LN dissection seems likely to
outweigh the potential benefit of PMRT.
Recently updated EBCTCG reports have reaffirmed the
benefit of PMRT in a subset of N1 patients who had axillary
dissection at least level II, irrespective of adjuvant systemic
therapy (mostly cyclophosphamide, methotrexate, and fluor-
ouracil).1 However, resistance to apply the results of older
studies to present practice remains, and the routine use ofommended. This is because the absolute
or death have decreased during recent
improved screening and treatment
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FIGURE 1. Kaplan–Meier (KM) overall survival (OS) and disease-
Medicine  Volume 94, Number 33, August 2015protocols. In other words, the characteristics of patients with
pT1/2N1 have changed favorably overtime. The widespread use
of sentinel LN (SLN) biopsy combined with extensive patho-
logic analysis has resulted in frequent identifications of nodal
micrometastasis, and a higher proportion of patients have now
been treated using modern systemic agents. Studies in the 1980s
reported the LRR rate of patients who did not undergo PMRT to
be 17.7%, whereas recent studies reported rates of 6% to 10%.1–
3 In this respect, the present absolute benefits of PMRT for
patients with T1/T2N1 breast cancer are likely to be small.
A subgroup analysis of the Danish Breast Cancer Coopera-
tive Group 82 b and c trials suggested that reduced LRR in
response to PMRT translated as a larger reduction in cancer
mortality in women with N1 breast cancer compared with those
with 4 positive LNs.4 Recent data from the National Cancer
Institute of Canada Clinical Trials Group MA.20 and the Euro-
pean Organization for Research and Treatment of Cancer 22922
trials indicated that optimized locoregional control is crucial for
long-term survival, especially in patients with a relatively lower
competing risk of distant metastasis (DM).5,6 From their stand-
point, PMRT does not only limit itself to locoregional control, but
also to the prevention of systemic progression. Here, we verified
the hypothesis that modern improvements in diagnostic and
therapeutic procedures have resulted in a lower risk of LRR
and superior survival in patients with T1/T2N1 breast cancer who
Chang et alwere treated with mastectomy and axillary LN dissection. We
subsequently evaluated the contribution of PMRT to survival
outcomes regarding overall recurrence as well as LRR.
METHODS
Patients
This retrospective observational study was approved by the
Institutional Review Board of Severance Hospital in Seoul,
Korea. Patient consent was not required, because the collected
data were existing information. We identified 1123 consecutive
patients who underwent upfront surgery and who were diag-
nosed with pathological T1N1/T2N1 breast cancer between
January 1998 and December 2011. Patients who underwent
breast conservation surgery (n¼ 431) were excluded. The data
from the remaining 692 patients were reviewed retrospectively.
Preoperative evaluation consisted of a complete history, a
physical examination, complete blood counts, mammography,
breast ultrasonography, a bone scan, and computed tomography
scans or magnetic resonance imaging, if indicated. Systemic
staging with [18F]-fluorodeoxyglucose-positron emission tom-
ography was performed in 109 patients (15.8%). Immunohis-
tochemical staining for estrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor receptor 2
(HER2) was performed. Breast cancer molecular subtypes were
categorized as luminal A (ERþ, moderate to strong PRþ, and
HER2); luminal B (ERþ, negative or weak PRþ, and
HER2þ/); HER2 (ER and PR and HER2þ); and triple
negative (ER and PR, HER2).7,8
Treatment
All 692 patients underwent modified radical mastectomy.
Although SLN sampling was first implemented at our institu-
tion in 2000, it was not commonly employed until 2003; thus,
SLN sampling was only performed in 357 patients (51.6%).
Those with biopsy-confirmed or suspicious axillary nodal
metastasis on positron emission tomography imaging were
spared. Surgeons did not refer all T1/T2N1 patients to radiation
2 | www.md-journal.comoncologists; PMRT was offered to patients with high-risk
features such as multiple positive LNs. Three-dimensional
conformal PMRT was applied to the chest and regional nodal
areas (supraclavicular, axillary, and internal mammary nodes)
using the reverse hockey stick technique with a total dose of
50.4Gy in 28 fractions.
Before the publication of the Cancer and Leukemia Group
B 9344 study (1998–2003), if patients had comorbidities such
as cardiac disease or a poor performance status, our institutional
policy for adjuvant chemotherapy for node-positive patients
was to offer 6 cycles of fluorouracil, doxorubicin, cyclopho-
sphamide or 6 cycles of cyclophosphamide, methotrexate, and
fluorouracil.9 After the Cancer and Leukemia Group B study
(2004–2011), most node-positive patients were offered a com-
bination of cyclophosphamide (600mg/m2) and doxorubicin
(60, 75, or 90mg/m2) for 4 cycles with or without an additional
4 cycles of paclitaxel (175mg/m2) (cyclophosphamide, doxor-
ubicin, and/or paclitaxel [ACT]). Trastuzumab therapy was
indicated for patients with HER2-overexpressing tumors. In
accordance with these policies, adjuvant systemic therapy was
selected after discussion with a medical oncologist.
Statistical Analyses
The cumulative incidences of LRR and DM were estimated
using the 1–Kaplan–Meiermethod, and the survival probabilities
of DFS and overall survival (OS) were estimated using the
Kaplan–Meier method. The time to recurrence or death was
calculated from the date of the mastectomy. Comparisons were
performed using a t-test (continuous variables) or the Chi-square
test (nominalvariables).Univariateanalyses for survivaloutcomes
were performed using the log-rank test. Multivariate analyses for
survival outcomes were performed using the Cox regression
model with stepwise backward elimination (alpha¼ 0.20). The
free survival (DFS) rates, and the 1–KM cumulative incidence of
locoregional recurrence (LRR) and distant metastasis (DM).level of statistical significance was set at P< 0.05. All statistical
analyses were performed with SPSS version 20.0 (IBM SPSS
Statistics, IBM Corporation, Armonk, NY).
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Comparison of Patient, Tumor, and Treatment Characteristics According to the Treatment Era (N¼692)
1998–2003 (n¼ 280) 2004–2011 (n¼ 412) P
Age (yr) <45 109 38.9% 124 30.1% 0.016
45 171 61.1% 288 69.9%
MeanSD 48.4 9.9 51.1 11.4 0.001
T stage T1 107 38.2% 203 49.3% 0.004
T2 173 61.8% 209 50.7%
T size, cm MeanSD 2.42 0.95 2.13 0.88 <0.001
Histological grade 1 27 10.7% 71 20.8% 0.002
2 169 66.8% 188 55.1%
3 57 22.5% 82 24.0%
EIC Negative 146 63.8% 246 61.5% 0.574
Positive 83 36.2% 154 38.5%
Size of LN metastasis Micro 4 1.4% 120 29.1% <0.001
Macro 276 98.6% 292 70.9%
No. of positive lymph nodes 1 137 48.9% 256 62.1% 0.001
2 88 31.4% 108 26.2%
3 55 19.6% 48 11.7%
Percentage of positive LNs <25% 272 97.1% 345 94.8% 0.138
25% 8 2.9% 19 5.2%
Estrogen receptor status Negative 98 35.5% 101 24.5% 0.002
Positive 178 64.5% 311 75.5%
Progesterone receptor status Negative 141 51.1% 144 35.0% <0.001
Positive 135 48.9% 268 65.0%
HER2 overexpression Negative 145 59.2% 294 74.8% <0.001
Positive 100 40.8% 99 25.2%
Sentinel LN biopsy Yes 25 8.9% 332 80.6% <0.001
No. of LN dissection MeanSD 18.4 6.5 15.9 7.0 <0.001
Chemotherapy 259 92.5% 373 90.5%
CMF 186 66.4% 62 15.0% <0.001
ACT 62 22.1% 298 72.3%
Unspecified 11 3.9% 13 3.2%
Trastuzumab No 100 100.0% 71 73.2% <0.001
Yes 0 0.0% 26 26.8%
Hormone therapy 180 65.5% 297 72.1% 0.064
Postmastectomy RT No 254 90.7% 315 76.5% <0.001
Yes 26 9.3% 97 23.5%
AC¼ adriamycin cyclophosphamide, CMF¼ cyclophosphamide methotrexate 5-fluorouracil, EIC¼ extensive intraductal component, HER2¼
¼ r
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The clinicopathological characteristics of the 692 patients
are shown in Supplementary Table 1, http://links.lww.com/MD/
A350. Briefly, SLN-positive patients underwent axillary LN
dissection (mean number of LN resected, 17.1 6.8). Most
patients received adjuvant systemic chemotherapy (632, 91.3%)
and/or endocrine therapy (477, 69.4%). Trastuzumab was
administered in 26 (13.2%) patients with HER2-overexpressing
tumors. PMRT was administered to 123 (17.8%) patients.
The median follow-up time among surviving patients
was 98 months (range, 2–197 months). Recurrence was
observed in 126 patients (18.2%). A total of 87 (12.6%)
patients died. The overall incidence of LRR and DM as the
first failure pattern was 7.5% (n¼ 52) and 12.9% (n¼ 89),
respectively, including 31 patients who suffered from simul-
human epidermal growth factor receptor type 2, LN¼ lymph node, RTtaneous LRR and DM. The 5-year cumulative incidences of
LRR and DM were 5.9% and 10%, and the 10-year rates were
9.3% and 13%, respectively (Figure 1). The 5-year DFS and
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.OS were 86.5% and 91.9%, respectively, and the 10-year rates
were 79.5% and 86%, respectively.
Entire Cohort (1998–2011)
The entire cohort was divided into 2 groups, the early-era
(1998–2003) and late-era (2004–2011) cohorts, because mod-
ern therapies including SLN biopsy, taxane-based chemother-
apy, and aromatase inhibitors have been commonly used since
2004 at our institution (Table 1). Comparisons of patient
characteristics for each cohort are listed in Table 1. Patient
characteristics have changed favorably overtime (eg, older
patients, less T2, smaller tumor size, lower grade tumors,
increased detection of micrometastasis, fewer positive LNs,
and a higher proportion of hormone-receptor positive tumors).
In addition, in late-era group SLN biopsy use was widespread
adiotherapy, SD¼ standard deviation, T¼ paclitaxel docetaxel.facilitating increased detection of micrometastasis in LNs, and
fewer numbers of positive LNs, postoperatively. Furthermore,




Chang et al Medicine  Volume 94, Number 33, August 2015using a modern chemotherapy regimen (ACT), anti-HER2
targeted agents, and PMRT (all P< 0.05). The median follow-
up of the early-era and late-era cohorts were 155 (range, 124–
197) months and 73 (range, 2–122) months, respectively.
Compared with the early-era cohort, the late-era cohort
had significantly better 5-year OS (88.6% vs 94.2%,
P¼ 0.009) and 5-year DFS (82.1% vs 89.3%, P¼ 0.007)
(Figure 2A, B). Improvement in DFS in the late-era cohort
was a consequence of a significant reduction in LRR and DM
(P< 0.001, Figure 2C, D). Notably, the 5-year LRRs were
10.3% (95% confidence interval [CI] 6.8%–13.8%) and 3.2%
(95% CI 1.4%–5.0%) for the early-era and late-era cohorts,
respectively.
Multivariate Cox regression analyses were performed to
analyze the factors independently associated with LRR, DM,
DFS, and OS (Table 2). Older age (45 years), smaller LN ratio
FIGURE 2. (A) Overall survival, (B) disease-free survival, (C) locoreg
T2N1 breast cancer (N¼692) according to treatment era (1998–(<25%), use of SLN biopsy, and administration of ACT were
significantly and independently associated with improved DFS.
T-stage, tumor grade, and use of PMRT were related to DFS, but
4 | www.md-journal.comwith borderline significance. Administration of the ACT was
significantly and independently associated with improved LRR
control, and having a nonhigh grade tumor showed borderline
significance. In an analysis of DM, old age (45 years), T1
tumor stage, nonhigh grade tumor, a smaller LN ratio (<25%),
SLN biopsy, and the chemotherapy regimen administered were
significantly and independently associated with improved
DM control.
Late Cohort (2004–2011)
To provide more clinically relevant information for current
practice from a relatively homogenous patient group, we
assessed the effect of PMRT on clinical outcomes limited to
the data from late-era group. Based on our previous experience,
LN status was the first consideration when determining the use
of PMRT. Understandably, patients treated with PMRT had
al recurrence, and (D) distant metastasis in all patients with T1N1/
03 vs 2004–2011).more LN macrometastasis and positive LNs than those who
were not treated with PMRT (all P< 0.05, Table 3). ACT
chemotherapy was more frequently administered to patients
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
LN tumor burden. The 3-year DM rate was 0%, 5.2%, and 9.8%
TABLE 2. Multivariate Cox Proportional Hazards Survival Analysis in the Entire Cohort According to Each Clinicopathological and
Treatment Variable
LRR Analysis DM Analysis DFS Analysis
Covariate HR 95% CI P HR 95% CI P HR 95% CI P
Year of mastectomy
04–11 vs 98–03 0.68 0.28–1.63 0.387 0.79 0.40–1.51 0.457 0.71 0.42–1.20 0.203
Age, years
<45 vs 45 1.54 0.81–2.91 0.187 2.25 1.38–3.68 0.001 1.83 1.22–2.75 0.003
T stage
T2 vs T1 1.33 0.74–2.42 0.342 1.74 1.04–2.90 0.034 1.44 0.98–2.13 0.064
Grade
III vs I-II 1.84 0.97–3.47 0.061 2.01 1.22–3.33 0.006 1.49 0.98–2.27 0.064
Lymph node involvement
2 vs 1 1.22 0.63–2.36 0.549 1.18 0.69–2.00 0.551 1.39 0.91–2.13 0.125
3 vs 1 1.00 0.43–2.34 0.993 1.02 0.52–1.99 0.951 1.30 0.77–2.20 0.324
Lymph node tumor deposits
Macro vs micro 1.09 0.34–3.52 0.889 2.09 0.71–6.14 0.178 1.26 0.63–2.50 0.516
Percentage of positive LNs
25% vs <25% 2.96 0.86–10.23 0.087 4.67 1.96–11.1 0.001 2.82 1.23–6.12 0.009
ER/PR status
Positive vs Negative 0.70 0.38–1.27 0.239 0.74 0.46–1.21 0.23 0.71 0.48–1.06 0.091
Use of SLN biopsy
Yes vs No 0.90 0.41–1.99 0.799 0.35 0.18–0.69 0.002 0.55 0.33–0.92 0.022
Adjuvant chemotherapy
CMF vs no 0.63 0.26–1.49 0.29 1.90 0.57–6.33 0.294 0.64 0.35–1.17 0.151
ACT vs No 0.19 0.06–0.58 0.003 1.33 0.38–4.64 0.652 0.36 0.18–0.70 0.003
Unspecified vs No 0.30 0.04–2.47 0.26 4.30 1.00–18.6 0.05 0.81 0.29–2.28 0.691
Use of PMRT
Yes vs No 0.50 0.11–2.26 0.365 0.54 0.22–1.35 1.9 0.46 0.20–1.03 0.059
AC¼ adriamycin cyclophosphamide, CI¼ confidence interval, CMF¼ cyclophosphamide methotrexate 5-fluorouracil, DFS¼ disease-free survi-
val, DM¼ distant metastasis, ER/PR¼ estrogen/progesterone receptor, HR¼ hazard ratio, LN¼ lymph node, LRR¼ locoregional recurrence,
¼ pa
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wise, disease and treatment characteristics were well balanced
between those who underwent PMRT and those who did not (all
P> 0.05).
The 5-year LRR rates were not significantly different
between those who underwent PMRT and those who did not
at 1% and 3.8%, respectively (Figure 3A). The 5-year DM rates
were not significantly different (Figure 3B). The 5-year DFS
rates were 96.1% and 87.5%, respectively, and the 10-year DFS
rates were 96.1% and 79.5%, respectively (P¼ 0.015)
(Figure 3C). The 5-year OS rates for patients who underwent
PMRT and those that did not were 100% and 91.9%, respect-
ively (P¼ 0.013) (Figure 3D).
In the multivariate analysis, PMRT (P¼ 0.038), nonhigh
grade tumor (P¼ 0.025), and ACT chemotherapy
(P¼ 0.007) were significantly and independently associated
with improved DFS (Table 4). To better assess the impact of
PMRT, we analyzed the data by excluding patients who did not
undergo chemotherapy. In these patients, PMRT (hazard ratio
[HR], 0.22; 95% CI 0.05–0.91) and macrometastasis (vs micro-
metastasis; HR, 2.89; 95% CI 1.20–6.94) were significantly and
independently associated with DFS. Multivariate analysis could
PMRT¼ postmastectomy radiotherapy, SLN¼ sentinel lymph node, Tnot be applied to assess the effect of PMRT on OS, since there
were no deaths in the PMRT group. To gain insight into
associations between the PMRT effect and size (macro- vs
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.micrometastasis) or number of positive LNs, we performed
subgroup analyses. The benefits of PMRT in DM control (HR,
0.13; 95% CI 0.02–0.99) and DFS (HR, 0.19; 95% CI 0.05–
0.78) were most apparent in patients with macrometastasis
compared to those with micrometastasis (Table 5).
In the late-era cohort, in patients with N1 disease who did
not undergo PMRT, the effect of LN tumor burden on the risk of
the tumor recurrence was assessed and is summarized in
Supplementary Table 2, http://links.lww.com/MD/A350. The
3-year LRR rate was not significantly different as a function of
LN tumor burden, whereas the DM risk increased according to
clitaxel docetaxel.for those with micrometastasis, SLN macrometastasis, and non-
SLN macrometastasis, respectively.
DISCUSSION
The 2005 EBCTCG pooled analysis showed a survival
benefit of PMRT when the 5-year LRR risk exceeded 10%.10
Their analysis evaluated the benefit of PMRT in patients who
underwent a mastectomy according to node positivity. Although
PMRT yielded similar proportional reductions in LRR irrespec-
tive of node positivity, the absolute reductions in LRR in node-
positive women were large and resulted in a clear survival
benefit. Therefore, PMRT was indicated in N2 disease;
www.md-journal.com | 5
TABLE 3. Comparison of Patient, Tumor, and Treatment Characteristics According to Postmastectomy Radiotherapy Use in 412
Patients Who Were Treated in the Late Era (2004–2011)
PMRT () (n¼ 315) PMRT (þ) (n¼ 97) P
Age, year <45 95 30.2% 29 29.9% 0.961
45 220 69.8% 68 70.1%
T stage T1 154 48.9% 49 50.5% 0.779
T2 161 51.1% 48 49.5%
Histological grade 1 55 20.1% 16 23.9% 0.778
2 153 55.8% 35 52.2%
3 66 24.1% 16 23.9%
EIC Negative 190 62.5% 56 58.3% 0.465
Positive 114 37.5% 40 41.7%
Size of LN metastasis Micro 100 31.7% 20 20.6% 0.035
Macro 215 68.3% 77 79.4%
No. of positive lymph nodes 1 209 66.3% 47 48.5% 0.006
2 73 23.2% 35 36.1%
3 33 10.5% 15 15.5%
Percentage of positive LNs <25% 281 95.3% 64 92.8% 0.401
25% 14 4.7% 5 7.2%
Estrogen receptor status Negative 79 25.1% 22 22.7% 0.631
Positive 236 74.9% 75 77.3%
Progesterone receptor status Negative 110 34.9% 34 35.1% 0.981
Positive 205 65.1% 63 64.9%
HER2 overexpression Negative 222 74.7% 72 75.0% 0.96
Positive 75 25.3% 24 25.0%
Chemotherapy 281 89.2% 92 94.9% 0.003
CMF 57 18.1% 5 5.2%
ACT 215 68.3% 83 85.6%
Unspecified 9 2.9% 4 4.1%
Trastuzumab No 53 72.6% 18 75.0% 0.818
Yes 20 27.4% 6 25.0%
Hormone therapy 230 73.0% 67 69.1% 0.449
AC¼ adriamycin cyclophosphamide, CMF¼ cyclophosphamide methotrexate 5-fluorouracil, EIC¼ extensive intraductal component, HER2¼ hu-
RT
Chang et al Medicine  Volume 94, Number 33, August 2015however, the benefit of PMRT in N1 disease, which is assumed
to have a relatively low absolute LRR risk, remained debatable.
Recently, an updated meta-analysis showed that LRR reduction
in response to PMRT mediated a significant survival benefit in
patients with N1 disease, regardless of systemic chemotherapy.1
Here, patients with T1/T2N1 disease who were treated
more recently (2004–2011) had lower risks of DM and LRR,
and had better survival compared with those who were treated
earlier (1998–2003). In recently treated patients who were at
very low risk for LRR, PMRT significantly improved DFS.
These findings indicate that recent advances in surgical and
systemic therapies might not negate the benefit of PMRT in N1
patients, and that a very low LRR rate should not be a surrogate
endpoint to exclude patients from PMRT.
A recent meta-analysis indicated that the 5-year LRR in a
series of patients who underwent PMRT between 1964 and
1986 was 2.8%,1 which was similar to that for the recently
treated patients in the present study (1%). In contrast, in the past,
the 5-year LRR in patients who did not undergo PMRT was as
high as 16.5%, whereas this has continually decreased over time
human epidermal growth factor receptor type 2, LN¼ lymph node, PMand was considerably low in our late-era cohort (3.8%).2,3,11 A
number of possibilities could underlie improvements in the 5-
year LRR, DFS, OS, and the rate of DM. First, the Korean
6 | www.md-journal.comnational cancer-screening program for breast cancer became
active during 2003–2005, meaning that the patient character-
istics of those with N1 disease have changed favorably over
time.12 Second, improvements in pathological diagnostic
methods have increased the detection of micrometastasis, which
might have been classified previously as N0 disease. Third, the
median age of Korean breast cancer patients has increased
overtime, which might affect treatment outcomes.12 Further-
more, increased use of more effective adjuvant systemic thera-
pies likely resulted in superior outcomes in recently treated
patients.13,14
To assess the impact of PMRT in the late-era cohort rather
than entire cohort was more clinically relevant, although the
cut-off point of 2003 was somewhat arbitrary. In the late-era
cohort, PMRT was not associated with a significant reduction in
LRR or DM risk, but was significantly associated with improve-
ments in DFS and OS, which resulted from possible reduction of
both LRR and DM by PMRT. In addition, PMRT prevented
subsequent progression of subclinical disease within the chest
wall and regional nodes (eg, supraclavicular and internal mam-
¼ postmastectomy radiotherapy, T¼ paclitaxel docetaxel.mary nodes) to systemic disseminations. These findings are
congruent with 2 recent clinical trials that addressed the clinical
benefit of adjuvant radiotherapy in breast-conserved patients.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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Medicine  Volume 94, Number 33, August 2015 Benefit of Postmastectomy Radiotherapy in N1 PatientsThe National Cancer Institute of Canada Clinical Trials Group
MA.20 trial enrolled patients with high-risk N0 and N1 disease
and randomly assigned them to treatment with or without
regional RT.5 In the preliminary report, regional radiotherapy
reduced the 5-year DM rate by 4.3% and reduced the LRR rate
by 2%. The European Organization for Research and Treatment
of Cancer 22922/10925 trial showed similar results; regional
radiotherapy reduced the 10-year DFS rate by 3%.6 In our study,
both ACT and PMRT were independently associated with an
improvement in DFS. This supports the hypotheses that radio-
therapy and systemic therapy have different time-dependent
effects15 and that the effects of radiotherapy and systemic
therapy are synergistic or additive rather than competitive.16
The benefit of PMRT on DFS was most apparent in
patients with macrometastasis compared with that in those with
micrometastasis. In addition, the risk of DM or any recurrence
FIGURE 3. (A) Locoregional recurrence, (B) distant metastasis, (C
(2004–2011) patients with T1N1/T2N1 breast cancer (n¼412) awas lower in patients with low LN tumor burden (microme-
tastasis) compared to that in those with macrometastasis. Mit-
tendorf et al17 reported similar survival in patients with
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.micrometastasis compared with node-negative patients. Since
SLN biopsy was validated as standard operating procedure in
2003, efforts have been made to assess the SLN using serial
sectioning of entire SLN rather than using 3 sections per axillary
LN.18,19 Such extensive pathologic analysis results in the
frequent identification of micrometastatic foci (2 mm,
N1mi), and in our opinion, the use of PMRT in patients with
small-volume LN disease should be conservative, potentially
avoiding local therapy overtreatment.
Risk-adaptive-personalized treatment is the current stan-
dard treatment in mastectomy patients with N1 disease. The
current international consensus does not recommend routine use
of PMRT unless there are additional adverse features.8 How-
ever, the indication and frequency of PMRT use varies signifi-
cantly between institutions, and many investigators have
identified various risk factors of LRR including young age
isease-free survival, and (D) overall survival in the late-era group
rding to the use of postmastectomy radiotherapy (PMRT).(eg,45 years),20,21 large tumor size (eg, T2 or>3 cm),11,21 LN
ratio (eg, >15%–25%),20,22–24 ER-status,20,25 lymphovascular
invasion,25,26 extranodal extension, a medially located tumor,20
www.md-journal.com | 7
TABLE 4. Stepwise Univariate and Multivariate Analyses Using Cox Regression Method for Disease-Free Survival in 412 Patients
Who Were Treated in the Late Era (2004–2011)
Univariate Analysis Multivariate Analysis

Variables HR 95% CI P HR 95% CI P
Age, year <45 vs 45 1.23 0.69–2.21 0.486 NI
T stage T2 vs T1 1.25 0.71–2.19 0.443 NI
Histological grade G3 vs G1/2 2.02 1.12–3.65 0.02 2.02 1.09–3.72 0.025
EIC Positive vs negative 1.26 0.69–2.28 NI
Size of lymph node metastasis Macro vs Micro 1.64 0.84–3.21 0.146 1.98 0.95–4.13 0.066
No. of positive lymph nodes 3 vs 1–2 1.18 0.53–2.63 0.683 NI
Percentage of positive lymph nodes 25% vs <25% 1.21 0.38–3.90 0.747 NI
Estrogen receptor status Positive vs negative 0.68 0.37–1.23 0.199 NI
Progesterone receptor status Positive vs negative 0.61 0.35–1.06 0.08 NI
HER2 overexpression Positive vs negative 1.00 0.52–1.92 0.998 NI
Chemotherapy No (reference) 0.047
CMF 0.75 0.31–1.82 0.529 0.59 0.24–1.44 0.243
ACT 0.36 0.16–0.79 0.011 0.33 0.15–0.74 0.007
Unspecified 0.77 0.16–3.62 0.739 0.55 0.11–2.67 0.461
Postmastectomy radiotherapy Yes vs No 0.26 0.08–0.84 0.024 0.22 0.05–0.92 0.038
AC¼ adriamycin cyclophosphamide, CI¼ confidence interval, CMF¼ cyclophosphamide methotrexate 5-fluorouracil, EIC¼ extensive intra-
ductal component, HER2¼ human epidermal growth factor receptor type 2, HR¼ hazard ratio, Macro¼macrometastasis, Micro¼micrometastasis,
T¼ paclitaxel docetaxel.
tepw
Chang et al Medicine  Volume 94, Number 33, August 2015inadequate axillary surgery,11 and an earlier treatment era (eg,
before 1997).11 However, our results suggest that a risk-adap-
tive approach should be considered based on overall recurrence
risk rather than LRR risk. In this regard, the results of the United
Kingdom Medical Research Council-SUPREMO trial, which is
a large randomized trial investigating the benefit of PMRT in
modern treatment regimens that has the primary end-point of
OS, are eagerly awaited.27
Our study has several limitations including those inherent
in retrospective analysis. The statistical analyses are incomplete
Variables were entered into multivariate Cox regression model in a s
any point if P was >0.20.because multivariate analysis for LRR and OS could not be
performed because none of the patients undergoing PMRT died.
In addition, patients who underwent PMRT had more LNs that
TABLE 5. Univariate Cox Proportional Hazards Survival Analysis A
to Metastasis Size and Positive Lymph Node Number
LRR Analysis
PMRT vs No PMRT N HR 95% C
Late-era cohort 412 0.29 0.04–2.2
[0,1-8]LN tumor deposits
Micrometastasis 120 0.04 0.00–>1
Macrometastasis 292 0.33 0.04–2.5
[0,1-8]No. of positive LN
1 256 0.04 0.00–16
2 108 0.53 0.06–4.5
3 48 NA
CI¼ confidence interval, DFS¼ disease-free survival, DM¼ distant m
recurrence, NA¼ not applicable, PMRT¼ postmastectomy radiotherapy.
8 | www.md-journal.comwere positive and were, therefore, more likely to receive
ACT chemotherapy, leading to potential selection bias.
However, it is noteworthy that PMRT had a protective effect
after controlling for these potentially confounding factors.
Routine use of internal mammary node irradiation in our study
should be taken into consideration to interpret the benefit of
PMRT, which may be important because all previous positive
trials of PMRT used internal mammary node irradiation.
In summary, patients with T1/T2N1 breast cancer who
were treated recently had a lower risk of LRR and DM with
ise backward elimination method if P was <0.20 and were removed atexcellent survival outcomes compared with those treated in the
past. PMRT significantly and independently improved DFS,
although reductions in LRR were not large or significant in
mong Patients in the Late-Era Cohort (2004–2011) According
DM Analysis DFS Analysis
I HR 95% CI HR 95% CI
3 0.29 0.07–1.23 0.26 0.08–0.84
00 2.38 0.23–24,5 0.59 0.07–4.66
6 0.13 0.02–0.99 0.19 0.05–0.78
3 0.04 0.00–12.1 0.04 0.00–3.73
3 0.42 0.05–3.51 0.45 0.10–2.05
0.75 0.08–7.34 0.37 0.04–3.01
etastasis, HR¼ hazard ratio, LN¼ lymph node, LRR¼ locoregional
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
27. Kunkler IH, Canney P, van Tienhoven G, et al. Elucidating the rolethose treated with contemporary multidisciplinary manage-
ment. We believe that the present study does not convincingly
support the routine use of PMRT in all patients with T1/T2N1
breast cancer. However, it does support the results of the recent
EBCTCG meta-analysis that PMRT improves LRR-free survi-
val, DFS, and cancer-specific survival in node-positive patients
in contemporary practice.1 Similar concerns regarding regional
radiotherapy in breast-conserved patients might be meaningful.
Further studies, ideally, well-designed and controlled, need to
be conducted to confirm our findings.
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